|
Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321
Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have entered into an agreement regarding the development, commercialization and manufacturing of Immutep’s ImmuFact IMP321.
More... |
| All times are GMT -7. The time now is 12:22 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021